Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 8 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 8 5.
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN II 8.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and metabolic processes; dextrose supplies glucose for energy; electrolytes maintain fluid and electrolyte balance.
Aminosyn II 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis when administered intravenously. It serves as a substrate for protein metabolism, promoting nitrogen retention and tissue repair.
Intravenous infusion: 500 mL/day initially, titrate to provide 1.5-2 g/kg/day of amino acids and 25-50 g/kg/day of dextrose; monitor electrolytes.
Intravenous infusion, typical adult dose is 1.0 to 1.5 g amino acids/kg/day, administered as part of total parenteral nutrition; rate not to exceed 0.1 g amino acids/kg/hour.
None Documented
None Documented
Amino acids: 0.5-2 hours (rapid clearance); dextrose: ~1-2 hours (insulin-dependent). Clinical context: Continuous IV infusion maintains steady state.
Variable; individual amino acids have half-lives ranging from minutes to hours. Clinical context: infusion rate and metabolic demand determine steady-state levels.
Renal (amino acids: ~80% reabsorbed, excess excreted unchanged; dextrose: primarily metabolized, small fraction excreted renally <5%; electrolytes: renal excretion proportional to intake and plasma levels).
Amino acids are primarily eliminated via metabolism; less than 10% is excreted renally as free amino acids. No significant biliary or fecal excretion.
Category C
Category C
Amino Acid Solution
Amino Acid Solution